CRF Connect Logo
  • Tracks & Learning Series
    VIEW ALL
  • Conferences
  • My Favorites

Endovascular

Devices and Complications Learning Series

Stents and Scaffolds

Advertisement

Endovascular >
Stents and Scaffolds

Episodes

Exemplary Cases From the LIFE-BTK Trial

Exemplary Cases From the LIFE-BTK Trial

20 min.

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

21 min.

Angiographic and Clinical Outcomes of the Thin-Strut MAGNITUDE Bioresorbable Scaffold in Patients with Below-the-Knee Arterial Disease: Early Results from the RESOLV I Trial

Angiographic and Clinical Outcomes of the Thin-Strut MAGNITUDE Bioresorbable Scaffold in Patients with Below-the-Knee Arterial Disease: Early Results from the RESOLV I Trial

9 min.

New BTK Bioresorbable Stent Technology: Life BTK, The MOTIV-BTK Trial and R3 Clinical Programs

New BTK Bioresorbable Stent Technology: Life BTK, The MOTIV-BTK Trial and R3 Clinical Programs

10 min.

Yes: There Is Always Room For Better Stents

Yes: There Is Always Room For Better Stents

24 min.

No: Current DES Are Better Than Ever

No: Current DES Are Better Than Ever

6 min.

R3 Vascular MAGNITUDE Bioresorbable Drug Eluting Scaffold

R3 Vascular MAGNITUDE Bioresorbable Drug Eluting Scaffold

6 min.

Bioresorbable Stent Technology for BTK Disease: Putting the Trials Into Perspective

Bioresorbable Stent Technology for BTK Disease: Putting the Trials Into Perspective

7 min.

Iliocaval Stenting and Reconstructions With Extreme Case Examples

Iliocaval Stenting and Reconstructions With Extreme Case Examples

12 min.

New technology update for CLI : Scaffolds

New technology update for CLI : Scaffolds

8 min.

Scaffolds Are Back: What's Old Is New

Scaffolds Are Back: What's Old Is New

7 min.

Role of Drug-Eluting Technologies as Definitive Therapy

Role of Drug-Eluting Technologies as Definitive Therapy

8 min.

Reflow Medical’s Temporary Spur DES System

Reflow Medical’s Temporary Spur DES System

3 min.

MOTIV BRS (REVA Vascular)

MOTIV BRS (REVA Vascular)

4 min.

APTITUDE PLLA BRS (R3 Vascular)

APTITUDE PLLA BRS (R3 Vascular)

4 min.

Hybrid Nano-Coating DES for BTK Disease

Hybrid Nano-Coating DES for BTK Disease

6 min.

First Safety and Efficacy Study of the Misago Stent in Lower Extremity Endovascular Interventions via Radial Access Approach

First Safety and Efficacy Study of the Misago Stent in Lower Extremity Endovascular Interventions via Radial Access Approach

8 min.

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

7 min.

Endovascular Sequestration of High-Risk Carotid Lesions Using the MicroNET-Covered Embolic Prevention Stent in Consecutive Patients With Symptoms or Signs of Carotid Stenosis-Related Cerebral Injury: An Investigator-Initiated, Intravascular, Ultrasound-Controlled, Multinational, Multispecialty Trial (CGuard OPTIMA)

Endovascular Sequestration of High-Risk Carotid Lesions Using the MicroNET-Covered Embolic Prevention Stent in Consecutive Patients With Symptoms or Signs of Carotid Stenosis-Related Cerebral Injury: An Investigator-Initiated, Intravascular, Ultrasound-Controlled, Multinational, Multispecialty Trial (CGuard OPTIMA)

5 min.

Have We Gotten to the Final Word on Paclitaxel Safety?

Have We Gotten to the Final Word on Paclitaxel Safety?

9 min.

This website uses cookies to ensure you get the best experience on our website. Read More